Patient and perioperative characteristics
| Variable | Total cohort | Open | Planned MIS | P value |
| Total No of patients | 147 | 37 | 110 | |
| Age (years) (median (range)) | 67 (50–96) | 63 (50–86) | 67 (50–96) | 0.1 |
| Body mass index (kg/m2) (median (range)) | 29.8 (18.9–54.8) | 28.9 (19–46.8) | 30.2 (18.9–54.8) | 0.4 |
| LOS (days) (median (range)) | 1 (0–21) | 4 (3–21) | 1 (0–6) | <0.001 |
| Operative time (min) (median (range)) | 187 (83–392) | 156 (83–330) | 191.5 (99–392) | 0.04 |
| Procedure (n (%)) | ||||
| Robotic | 92 (63) | 0 (0) | 92 (84) | |
| Laparoscopic | 14 (9) | 0 (0) | 14 (13) | |
| Open | 41 (28) | 37 (100) | 4 (4) | |
| Planned MIS | 110 (75) | 0 (0) | 108 (100) | |
| Completed MIS | 106 (96) | 0 (0) | 106 (97) | |
| Converted | 4 (2.7) | 0 (0) | 4 (3.6) | |
| Stage (n (%)) | ||||
| I | 92 (63) | 21 (57) | 71 (65) | 0.11 |
| II | 3 (2) | 0 (0) | 3 (3) | |
| III | 32 (22) | 7 (19) | 25 (23) | |
| IV | 20 (14) | 9 (24) | 11 (10) | |
| Histology (n (%)) | ||||
| Homologous | 72 (49) | 11 (30) | 61 (56) | 0.02 |
| Heterologous | 65 (44) | 23 (62) | 42 (38) | |
| Not reported | 10 (7) | 3 (8) | 7 (6) | |
| Nodal assessment method (n (%)) | ||||
| SLN alone | 45 (31) | 5 (14) | 40 (36) | <0.001 |
| LND alone | 30 (20) | 16 (43) | 14 (13) | |
| SLN+LND | 61 (42) | 12 (32) | 49 (45) | |
| No assessment | 11 (7) | 4 (11) | 7 (6) | |
| Nodal basins assessed (n (%)) | ||||
| Pelvic only | 94 (64) | 23 (62) | 71 (65) | 0.93 |
| Pelvic and para-aortic | 42 (29) | 10 (27) | 32 (29) | |
| No assessment | 11 (7) | 4 (11) | 7 (6) | |
| Lymph nodes removed (n) (median (range)) | 6 (1–45) | 6 (1–45) | 6 (1–41) | 0.28 |
| Year of surgery (n (%)) | ||||
| 2009 | 20 (14) | 6 (16) | 14 (13) | 0.06 |
| 2010 | 6 (4) | 3 (8) | 3 (3) | |
| 2011 | 9 (6) | 4 (11) | 5 (5) | |
| 2012 | 18 (12) | 3 (8) | 15 (14) | |
| 2013 | 18 (12) | 3 (8) | 15 (14) | |
| 2014 | 16 (11) | 5 (14) | 11 (10) | |
| 2015 | 18 (12) | 3 (8) | 15 (14) | |
| 2016 | 21 (14) | 1 (3) | 20 (18) | |
| 2017 | 20 (14) | 8 (22) | 12 (11) | |
| 2018 | 1 (<1) | 1 (3) | 0 (0) | |
| Adjuvant treatment (n (%)) | ||||
| No | 12 (8) | 4 (11) | 8 (7) | 0.5 |
| Yes | 135 (92) | 33 (89) | 102 (93) | |
| Type of adjuvant treatment (n (%)) | ||||
| None | 12 (8) | 4 (11) | 8 (7) | 0.6 |
| Chemotherapy alone | 34 (23) | 11 (30) | 23 (21) | |
| IVRT alone | 5 (3) | 1 (3) | 4 (4) | |
| WPRT alone | 3 (2) | 0 (0) | 3 (3) | |
| Chemotherapy+IVRT | 85 (58) | 18 (49) | 67 (61) | |
| Chemotherapy+WPRT | 6 (4) | 2 (5) | 4 (4) | |
| Chemotherapy+IVRT/EBRT | 2 (1) | 1 (3) | 1 (1) |
EBRT, external beam radiation therapy; IVRT, intravaginal radiation therapy; LND, lymphadenectomy; LOS, length of hospital stay; MIS, minimally invasive surgery; SLN, sentinel lymph node; WPRT, whole pelvic radiation therapy.